| 1 |
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis
C. Roubille, Vincent Richer, Tara Starnino et al. · Annals of the Rheumatic Diseases
ReviewOpen access |
6 Jan 2015 |
908 |
| 2 |
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar et al. · Journal of Allergy and Clinical Immunology
Open access |
5 Sep 2018 |
701 |
| 3 |
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus
Lasse Roger Braathen, Rolf‐Markus Szeimies, Nicole Basset‐Séguin et al. · Journal of the American Academy of Dermatology
|
25 Dec 2006 |
662 |
| 4 |
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Eric Lawrence Simpson, Rodney Daniel Sinclair, Seth B. Forman et al. · The Lancet
Open access |
Jul 2020 |
516 |
| 5 |
A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis
Kim Alexander Papp, Kristian Reich, Carle F. Paul et al. · British Journal of Dermatology
Open access |
25 Feb 2016 |
470 |
| 6 |
Topical tofacitinib for atopic dermatitis: a phase II a randomized trial
Robert Bissonnette, Kim Alexander Papp, Yves P. Poulin et al. · British Journal of Dermatology
Open access |
16 Jul 2016 |
422 |
| 7 |
Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial
Thomas Ruzicka, Charles W Lynde, Gregor B. E. Jemec et al. · British Journal of Dermatology
|
21 Feb 2008 |
412 |
| 8 |
Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
Eric Lawrence Simpson et al. · British Journal of Dermatology
|
30 Jan 2020 |
391 |
| 9 |
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council
Yael Renert‐Yuval, Jacob Pontoppidan Thyssen, Robert Bissonnette et al. · Journal of Allergy and Clinical Immunology
Open access |
28 Jan 2021 |
349 |
| 10 |
A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette et al. · New England Journal of Medicine
Open access |
8 Jul 2015 |
305 |
| 11 |
A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin
Corrie L. Gallant‐Behm, Joseph Piper, Joshua M. Lynch et al. · Journal of Investigative Dermatology
Open access |
22 Nov 2018 |
288 |
| 12 |
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Sondergaard Deleuran et al. · Journal of the American Academy of Dermatology
Open access |
30 Jul 2019 |
259 |
| 13 |
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
Melinda Gooderham, Seth B. Forman, Robert Bissonnette et al. · JAMA Dermatology
Open access |
2 Oct 2019 |
244 |
| 14 |
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis
Chris Callewaert, Teruaki Nakatsuji, Rob Knight et al. · Journal of Investigative Dermatology
Open access |
25 Jun 2019 |
226 |
| 15 |
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
Emma Guttman‐Yassky, Ana Brânduşa Pavel, Lisa Ya Zhou et al. · Journal of Allergy and Clinical Immunology
Open access |
7 Feb 2019 |
226 |
| 16 |
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis
Helen Mengze He, Robert Bissonnette, Jianni Wu et al. · Journal of Allergy and Clinical Immunology
|
21 Jul 2020 |
225 |
| 17 |
Daylight photodynamic therapy for actinic keratosis: an international consensus
Stine Regin Wiegell, Hans Christian Wulf, Rolf‐Markus Szeimies et al. · Journal of the European Academy of Dermatology and Venereology
|
23 Dec 2011 |
219 |
| 18 |
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis
Margitta Worm et al. · JAMA Dermatology
Open access |
26 Dec 2019 |
215 |
| 19 |
Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study
Alexa B. Kimball, Kim Alexander Papp, Yasmine S. Wasfi et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
20 Dec 2012 |
214 |
| 20 |
Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL ‐17A inhibition in psoriasis
Kristian Reich et al. · Experimental Dermatology
Open access |
2 Apr 2015 |
211 |
| 21 |
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Eric Lawrence Simpson, Kim Alexander Papp, Andrew Blauvelt et al. · JAMA Dermatology
Open access |
9 Mar 2022 |
209 |
| 22 |
A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis
W.C. Ports, Sairah M. Khan, Shu-Ping Lan et al. · British Journal of Dermatology
Open access |
6 Feb 2013 |
204 |
| 23 |
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study)
Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
14 Feb 2018 |
200 |
| 24 |
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
Mark Lebwohl, Linda Stein Gold, Bruce E Strober et al. · New England Journal of Medicine
|
8 Dec 2021 |
194 |
| 25 |
Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis
Shunya Mashiko, Salim Bouguermouh, Manuel Rubio et al. · Journal of Allergy and Clinical Immunology
|
16 Mar 2015 |
187 |
| 26 |
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis
Eric Lawrence Simpson et al. · Journal of the American Academy of Dermatology
|
27 Apr 2020 |
185 |
| 27 |
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent
Robert Bissonnette, Linda Stein Gold, David S. Rubenstein et al. · Journal of the American Academy of Dermatology
Open access |
3 Nov 2020 |
184 |
| 28 |
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial
Andrew Blauvelt et al. · British Journal of Dermatology
Open access144 authors |
30 Dec 2019 |
176 |
| 29 |
A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris
Roland Kaufmann, Adrian Bibby, Robert Bissonnette et al. · Dermatology
|
2002 |
164 |
| 30 |
Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies
Marjolein S. de Bruin-Weller, Tilo M. Biedermann, Robert Bissonnette et al. · Acta Dermato Venereologica
Open access |
2021 |
150 |
| 31 |
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial
Robert Bissonnette, Lars Iversen, Howard L. Sofen et al. · British Journal of Dermatology
|
21 Nov 2014 |
149 |
| 32 |
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials
Thomas R.M. Bieber, Jacob Pontoppidan Thyssen, Kristian Reich et al. · Journal of the European Academy of Dermatology and Venereology
Open access |
18 Sep 2020 |
148 |
| 33 |
Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis
Ana Brânduşa Pavel, Teresa Song, Hyun Je Kim et al. · Journal of Allergy and Clinical Immunology
|
26 Jul 2019 |
146 |
| 34 |
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)
Eric Lawrence Simpson, Seth B. Forman, Jonathan I. Silverberg et al. · Journal of the American Academy of Dermatology
Open access |
17 Feb 2021 |
138 |
| 35 |
Feasibility Analysis of a Novel Cell Equalizer Topology for Plug-In Hybrid Electric Vehicle Energy-Storage Systems
Pablo A. Cassani, Sheldon S. Williamson · IEEE Transactions on Vehicular Technology
|
9 Sep 2009 |
138 |
| 36 |
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab
Heena Mehta, Shunya Mashiko, Julianty Angsana et al. · Journal of Investigative Dermatology
Open access |
30 Jan 2021 |
136 |
| 37 |
Socioeconomic Burden of Immune-Mediated Inflammatory Diseases -- Focusing on Work Productivity and Disability
Philip Jacobs, Robert Bissonnette, Lyn Guenther · Journal of Rheumatology Supplement
Open access |
Nov 2011 |
135 |
| 38 |
Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Diamant Thaçi, Mette Sondergaard Deleuran et al. · American Journal of Clinical Dermatology
Open access |
17 Jun 2020 |
134 |
| 39 |
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
Bruce E Strober, Craig L. Leonardi, Kim Alexander Papp et al. · Journal of the American Academy of Dermatology
Open access |
23 Nov 2016 |
131 |
| 40 |
Increased expression of IL ‐17A and limited involvement of IL ‐23 in patients with palmo‐plantar ( PP ) pustular psoriasis or PP pustulosis; results from a randomised controlled trial
Robert Bissonnette, Simon Nigen, Richard G B Langley et al. · Journal of the European Academy of Dermatology and Venereology
|
24 Sep 2013 |
131 |
| 41 |
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study
Robert Bissonnette, Catherine Maari, Seth B. Forman et al. · British Journal of Dermatology
Open access |
28 Mar 2019 |
130 |
| 42 |
Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
Robert Bissonnette, Ana Brânduşa Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology
Open access |
13 Aug 2019 |
129 |
| 43 |
Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis
Caitriona Ryan et al. · British Journal of Dermatology
Open access |
10 May 2018 |
126 |
| 44 |
Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies
Kim Alexander Papp, Boulos Paul Haraoui, Deepali Kumar et al. · Journal of Cutaneous Medicine and Surgery
Open access |
21 Nov 2018 |
125 |
| 45 |
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
Evgeny V. Berdyshev, Elena Goleva, Robert Bissonnette et al. · Allergy
Open access |
11 Jul 2022 |
115 |
| 46 |
ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation
Juan Manuel Leyva-Castillo, C Galand, Shunya Mashiko et al. · Journal of Allergy and Clinical Immunology
Open access |
14 Mar 2020 |
113 |
| 47 |
Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis
Shunya Mashiko, Heena Mehta, Robert Bissonnette et al. · Journal of Dermatological Science
|
15 Jul 2017 |
108 |
| 48 |
Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck, Mette Sondergaard Deleuran, Robert Bissonnette et al. · American Journal of Clinical Dermatology
Open access |
May 2022 |
106 |
| 49 |
Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema
Robert Bissonnette, Margitta Worm, B. Gerlach et al. · British Journal of Dermatology
|
10 Nov 2009 |
105 |
| 50 |
Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review
Patrick Joseph Fleming, C. Roubille, Vincent Richer et al. · Journal of the European Academy of Dermatology and Venereology
Review |
10 Dec 2014 |
105 |